NCT05325528View on ClinicalTrials.gov

Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 10, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Liver Metastases
Interventions
DRUG

Tislelizumab in Combination with Oxaliplatin and Tegafur

6 cycles of Tislelizumab plus SOX regimen every 21 days

Trial Locations (1)

310000

RECRUITING

gastrointestinal department of second affiliated hospital of Zhejiang University, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER